![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
Dr. Tim Pardee is a physician scientist at Atrium Health Wake Forest Baptist in North Carolina. The goal of Dr. Pardee’s lab is to find new agents that treat AML and MDS. At the 2023 ASCO conference, he shared details with HealthTree about his early stage research aimed at providing a treatment option for AML patients with the P53 mutation. You can read Dr. Pardee’s ASCO abstract here.
Learn About Dr. Pardee's Research
Video Summary
Having a mutation in the P53 gene often makes a patient’s AML more aggressive and less responsive to current therapies. Dr. Pardee acknowledges there is a real need to develop new and more effective drugs for these patients. In collaboration with another scientist at his facility, Dr. Pardee is working to develop a drug that attacks AML cells differently than traditional chemotherapy. The goal is for this drug to be used against P53 mutations as they tend to be very chemotherapy resistant. This new drug is called Capped F10 (CP10), and in the lab, cells have shown to be very responsive and sensitive to the drug. In animal models, Dr. Pardee has found that the use of this drug leads to a statistically significant improvement in survival when compared to standard chemotherapies typically used to treat AML. Dr. Pardee acknowledges that while the development of this drug is very early and is still several years away from being tested in humans, he is hopeful that CP10 will become a successful treatment option for patients with P53 mutated AML in the near future.
Dr. Tim Pardee is a physician scientist at Atrium Health Wake Forest Baptist in North Carolina. The goal of Dr. Pardee’s lab is to find new agents that treat AML and MDS. At the 2023 ASCO conference, he shared details with HealthTree about his early stage research aimed at providing a treatment option for AML patients with the P53 mutation. You can read Dr. Pardee’s ASCO abstract here.
Learn About Dr. Pardee's Research
Video Summary
Having a mutation in the P53 gene often makes a patient’s AML more aggressive and less responsive to current therapies. Dr. Pardee acknowledges there is a real need to develop new and more effective drugs for these patients. In collaboration with another scientist at his facility, Dr. Pardee is working to develop a drug that attacks AML cells differently than traditional chemotherapy. The goal is for this drug to be used against P53 mutations as they tend to be very chemotherapy resistant. This new drug is called Capped F10 (CP10), and in the lab, cells have shown to be very responsive and sensitive to the drug. In animal models, Dr. Pardee has found that the use of this drug leads to a statistically significant improvement in survival when compared to standard chemotherapies typically used to treat AML. Dr. Pardee acknowledges that while the development of this drug is very early and is still several years away from being tested in humans, he is hopeful that CP10 will become a successful treatment option for patients with P53 mutated AML in the near future.
about the author
Katie Braswell
Katie joined HealthTree as the Community Director for AML in 2021. She is a registered dietitian who previously worked at the VA hospital in Dallas, Texas where she coached veterans with blood cancer on how to use nutrition to improve their treatment outcomes and minimize cancer-related side effects. Katie is passionate about health education and patient empowerment. In her spare time, she loves to experiment with new recipes in the kitchen, spend time running outdoors and travel to new places.
